The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-21-033.
Who won it before
93 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $52,336,860 in first-year total cost, median $593,078.
Most frequent study sections
- Clinical Oncology Study Section[CONC]47
- Imaging Guided Interventions and Surgery Study Section[IGIS]7
- Cancer Immunopathology and Immunotherapy Study Section[CII]6
- Radiation Therapeutics and Biology Study Section[RTB]6
- Clinical Translational Imaging Science Study Section[CTIS]4
Most frequent institutions
- SLOAN-KETTERING INST CAN RESEARCH9
- UNIVERSITY OF TX MD ANDERSON CAN CTR8
- OHIO STATE UNIVERSITY7
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE6
- JOHNS HOPKINS UNIVERSITY5
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Validation of epigenomic biomarkers for thyroid cancer diagnostics1R01CA241845-01A1 | HAHN, MARIAYIM, JOHN H | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $958,109 | CBSS |
| 2021 | Tumor Subtypes and Therapy Response in Pancreatic Cancer2R01CA199064-06A1 | TSAI, SUSANYEH, JEN JEN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $806,124 | CONC |
| 2021 | Personalized Adoptive T-cell Therapy for AML1R01CA262629-01 | AVIGAN, DAVID E.ROSENBLATT, JACALYN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $762,763 | CONC |
| 2021 | Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal2R01CA143130-11A1 | NAKAGAWA, MAYUMI | UNIV OF ARKANSAS FOR MED SCIS, AR | $727,272 | CONC |
| 2021 | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients1R01CA260872-01 | AMIN, HESHAM MDUDA, DAN GABRIELKASEB, AHMED | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $711,171 | CONC |
| 2021 | CAR T Cells for Advanced Thyroid Cancer1R01CA254035-01A1 | FAHEY, THOMAS JJIN, MOONSOO M.VAN BESIEN, KOEN WALTER | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $693,091 | CONC |
| 2021 | Targeting obesity to improve survival from childhood acute lymphoblastic leukemia1R37CA252236-01A1 | ORGEL, ETAN | CHILDREN'S HOSPITAL OF LOS ANGELES, CA | $687,010 | CONC |
| 2021 | Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas1R01CA263500-01 | MACKALL, CRYSTALMONJE-DEISSEROTH, MICHELLE | STANFORD UNIVERSITY, CA | $671,445 | CONC |
| 2021 | Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring1R01CA256740-01 | AGGARWAL, RAHULVIGNERON, DANIEL B | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $669,448 | IGIS |
| 2021 | Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism1R01CA262388-01 | DENKO, NICHOLAS C.LI, ZIHAIWILLIAMS, TERENCE MARQUES | OHIO STATE UNIVERSITY, OH | $650,406 | ZRG1 |
| 2021 | Pacritinib in rel/refr T-cell lymphomas1R01CA265929-01 | WILCOX, RYAN A | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $645,497 | CONC |
| 2021 | Multi-receptor Targeting of Glioblastoma1R01CA256285-01A1 | DEBINSKI, WALDEMAR | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $642,795 | CONC |
| 2021 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer1R01CA248147-01A1 | YOON, HARRY H | MAYO CLINIC ROCHESTER, MN | $640,182 | CONC |
| 2021 | Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer1R01CA260678-01 | DONAHUE, TIMOTHY RRADU, CAIUS GABRIELWAINBERG, ZEV A | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $634,454 | DT |
| 2021 | Targeting B7-H3 in ovarian cancer1R01CA256898-01 | DOTTI, GIANPIETROGEHRIG, PAOLA ALVAREZ | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $632,310 | ZRG1 |
| 2021 | A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients1R01CA255639-01A1 | PAIK, PAUL KRIESS, JONATHAN W | SLOAN-KETTERING INST CAN RESEARCH, NY | $628,641 | CONC |
| 2021 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)1U01CA252048-01A1 | CHI, PING | SLOAN-KETTERING INST CAN RESEARCH, NY | $622,197 | DT |
| 2021 | Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response1R01CA255650-01A1 | CURTI, BRENDAN DREDMOND, WILLIAM L | PROVIDENCE PORTLAND MEDICAL CENTER, OR | $593,078 | CONC |
| 2021 | Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients1R01CA255960-01 | KEYOMARSI, KHANDAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $587,495 | CONC |
| 2021 | Training Swallowing Initiation during Expiration: Impact on Safety and Efficiency Following Treatment for Oropharyngeal Head and Neck Cancer1R01CA262502-01 | MARTIN-HARRIS, BONNIE J | NORTHWESTERN UNIVERSITY, IL | $586,422 | MFSR |
| 2021 | Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial2R01CA197296-06 | JAFFEE, ELIZABETH M.ZHENG, LEI | JOHNS HOPKINS UNIVERSITY, MD | $581,039 | CONC |
| 2021 | Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer1R01CA248741-01A1 | CARBONE, DAVID P.DIKOV, MIKHAIL M | OHIO STATE UNIVERSITY, OH | $577,069 | CONC |
| 2021 | Reduction of Tumor-Positive Margins in Oncology Surgery1R37CA245157-01A1 | WARRAM, JASON MORGAN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $563,251 | CONC |
| 2021 | Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma1R37CA258346-01 | WAHL, DANIEL R | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $554,870 | RTB |
| 2021 | Re-wiring PDAC Tumor Immunity Through Dendritic Cells1R01CA262506-01 | DENARDO, DAVID GDESELM, CARL | WASHINGTON UNIVERSITY, MO | $551,987 | CII |
| 2021 | Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma1R01CA257265-01 | DAVAR, DIWAKARZAROUR, HASSANE M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $551,927 | CONC |
| 2021 | Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms1R37CA259260-01 | DIAMOND, ELI LOUS | SLOAN-KETTERING INST CAN RESEARCH, NY | $551,042 | CONC |
| 2021 | Targeted Therapies for Lymphoid Malignancies2R01CA177292-06A1 | ROGERS, KERRY ANNEWOYACH, JENNIFER A. | OHIO STATE UNIVERSITY, OH | $538,241 | CONC |
| 2021 | Novel combination therapy for AML expressing mutant RUNX11R01CA262636-01 | BHALLA, KAPILDINARDO, COURTNEYTAKAHASHI, KOICHI | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $534,187 | CONC |
| 2021 | Precision targeting of T cell cytotoxicity with PET1R01CA258297-01 | AGGARWAL, RAHULCRAIK, CHARLES SCOTTEVANS, MICHAEL JOHNFONG, LAWRENCE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $524,205 | CTIS |
| 2021 | Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer1R01CA262580-01 | GERBER, SCOTT ANDREWLINEHAN, DAVID C | UNIVERSITY OF ROCHESTER, NY | $516,038 | CONC |
| 2021 | Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia1R01CA265095-01 | BUDDE, LIHUA ELIZABETHCALIGIURI, MICHAEL AYU, JIANHUA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $489,159 | CONC |
| 2021 | Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas1R37CA251978-01A1 | SAYOUR, ELIAS | UNIVERSITY OF FLORIDA, FL | $472,806 | CII |
| 2021 | Improving efficacy of radioiodine treatment of thyroid cancer1R01CA249663-01A1 | FAGIN, JAMES AHO, ALAN L. | SLOAN-KETTERING INST CAN RESEARCH, NY | $471,416 | MCE |
| 2021 | Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy1R01CA249151-01A1 | FUJIMOTO, JAMES G | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $466,284 | IGIS |
| 2021 | Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment1R01CA249811-01A1 | MARANCHIE, JODI KATHLEENSTORKUS, WALTER J. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $456,744 | CII |
| 2021 | Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer1R01CA249279-01A1 | HALABI, SUSANRYAN, CHARLES JAMESSHARIFI, NIMA | UNIVERSITY OF MINNESOTA, MN | $426,729 | CONC |
| 2021 | Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD1R01CA252469-01A1 | CHOE, HANNAHRANGANATHAN, PARVATHI | OHIO STATE UNIVERSITY, OH | $415,000 | CONC |
| 2021 | A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib1R01CA225913-01A1 | ALTIERI, DARIO COLSZANSKI, ANTHONY J. | WISTAR INSTITUTE, PA | $410,285 | CONC |
| 2021 | Robot-Assisted Personalized Prostate Biopsy1R01CA247959-01A1 | STOIANOVICI, DAN | JOHNS HOPKINS UNIVERSITY, MD | $316,306 | BTSS |
| 2021 | Two photon fluorescence microscopy for dermatologic surgery and biopsy1R37CA258376-01 | GIACOMELLI, MICHAEL GENE | UNIVERSITY OF ROCHESTER, NY | $308,061 | IGIS |
| 2020 | Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma1R01CA254271-01 | BADIE, BEHNAMBROWN, CHRISTINE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $768,221 | CONC |
| 2020 | Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients1R37CA252312-01 | LAROCCA, CECILIA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $759,496 | CONC |
| 2020 | Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection1R01CA241758-01A1 | ALLAF, MOHAMADHU, JIMSCHAEFFER, EDWARD MATTHEW | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $737,794 | NRCS |
| 2020 | A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers1R01CA238392-01A1 | LEE, NANCY Y | SLOAN-KETTERING INST CAN RESEARCH, NY | $716,756 | RTB |
| 2020 | Conformal Total Body and Marrow Irradiation for Leukemia2R01CA154491-07A1 | HUI, SUSANTA KWONG, JEFFREY Y | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $708,512 | RTB |
| 2020 | Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel1R01CA252940-01 | MAUS, MARCELA VALDERRAMA | MASSACHUSETTS GENERAL HOSPITAL, MA | $697,200 | CONC |
| 2020 | Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)1U01CA238444-01A1 | CERCEK, ANDREAIACOBUZIO-DONAHUE, CHRISTINE AJARNAGIN, WILLIAM ROBERT | SLOAN-KETTERING INST CAN RESEARCH, NY | $682,721 | CONC |
| 2020 | Tailoring CAR T cell therapy for Hodgkin Lymphoma1R01CA247497-01A1 | SAVOLDO, BARBARA | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $634,693 | CONC |
| 2020 | Pneumatic Drill and Robot for MRI-Guided Pediatrics Long Bone Biopsy1R01CA248191-01 | CLEARY, KEVIN R.SHARMA, KARUN V | CHILDREN'S RESEARCH INSTITUTE, DC | $631,110 | IGIS |
| 2020 | Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer1R01CA247471-01 | BATRA, SURINDER K.JAIN, MANEESHSALGIA, RAVI | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $614,511 | CONC |
| 2020 | Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition1R01CA244936-01A1 | WEBER, JEFFREY S | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $610,766 | CBSS |
| 2020 | Fluorescence-guided resection of breast tumors using a topically-applied molecular probe1R01CA246678-01 | BASILION, JAMES PETER | CASE WESTERN RESERVE UNIVERSITY, OH | $595,998 | IPCA |
| 2020 | Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)1R01CA239694-01A1 | MANNING, HENRY CHARLES | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $585,790 | CTIS |
| 2020 | Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer1R01CA238387-01A1 | TRAN, DAVID D | UNIVERSITY OF FLORIDA, FL | $521,764 | CONC |
| 2020 | Understanding Richter's Transformation in the targeted therapies era1R01CA240493-01A1 | LAPALOMBELLA, ROSA | OHIO STATE UNIVERSITY, OH | $474,404 | CONC |
| 2020 | Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults1R01CA249211-01 | CHOI, SUNG WON | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $466,089 | CONC |
| 2020 | Microbubble Cavitation for Improving Hepatocellular Carcinoma Radioembolization1R01CA238241-01A1 | EISENBREY, JOHNSHAW, COLETTE | THOMAS JEFFERSON UNIVERSITY, PA | $454,127 | RTB |
| 2020 | Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity1R01CA248917-01 | DENARDO, DAVID GKIM, HYUNSCHWARZ, JULIE KRISTINA | WASHINGTON UNIVERSITY, MO | $453,504 | RTB |
| 2020 | [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors1R01CA240638-01A1 | KUMMAR, SHIVAANIMARI APARICI, CARINA | STANFORD UNIVERSITY, CA | $423,444 | CTIS |
| 2020 | Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma1R01CA245969-01A1 | SONABEND, ADAM MSTUPP, ROGER | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $419,323 | CONC |
| 2020 | Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles1R01CA243085-01A1 | BRADBURY, MICHELLE STOUIJER, ABDELKRIM K.WIESNER, ULRICH | SLOAN-KETTERING INST CAN RESEARCH, NY | $396,582 | IGIS |
| 2020 | Small Molecule PSMA-Targeted Alpha Therapy2R01CA184228-06 | POMPER, MARTIN GZALUTSKY, MICHAEL ROD | JOHNS HOPKINS UNIVERSITY, MD | $319,250 | IPCA |
| 2020 | Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer1R01CA246553-01A1 | SHAH, MANISHA HWILLIAMS, TERENCE MARQUES | OHIO STATE UNIVERSITY, OH | $193,780 | MCE |
| 2020 | CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications1R01CA248398-01 | LANDGREN, CARL OLAULANER, GARY ALLAN | SLOAN-KETTERING INST CAN RESEARCH, NY | $135,622 | IGIS |
| 2019 | A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma1R01CA235667-01A1 | ADUSUMILLI, PRASAD S.ZAUDERER, MARJORIE G. | SLOAN-KETTERING INST CAN RESEARCH, NY | $727,344 | CONC |
| 2019 | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)1R01CA235620-01A1 | FREDERICK, MITCHELL J.JANKU, FILIPJOHNSON, FAYE | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $666,259 | CONC |
| 2019 | Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma1R01CA236500-01 | BADIE, BEHNAMBROWN, CHRISTINE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $665,839 | CII |
| 2019 | Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma1R01CA235800-01A1 | BRENNER, ANDREW JACOB | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $660,911 | CONC |
| 2019 | Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)1R01CA235681-01A1 | HAHN, NOAH M | JOHNS HOPKINS UNIVERSITY, MD | $656,816 | CONC |
| 2019 | Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma1R01CA239462-01A1 | CHAUMEIL, MYRIAM MARIANNERUBENSTEIN, JAMES LOUIS | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $650,020 | CONC |
| 2019 | Multi-site adaptive trial of a technology-based, EHR-integrated physical activity intervention in breast and endometrial cancer survivors1R37CA225877-01A1 | CADMUSBERTRAM, LISA ANNEPHILLIPS, SIOBHAN MARIE | UNIVERSITY OF WISCONSIN-MADISON, WI | $646,190 | ZCA1 |
| 2019 | Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies1R01CA235633-01 | COLEVAS, A. DIMITRIOS | STANFORD UNIVERSITY, CA | $629,493 | CONC |
| 2019 | Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes1R01CA226992-01A1 | JANI, ASHESHSCHUSTER, DAVID MICHAEL | EMORY UNIVERSITY, GA | $629,419 | RTB |
| 2019 | Targeting Neoantigens in Triple Negative Breast Cancer1R01CA240983-01 | GILLANDERS, WILLIAM E.SCHREIBER, ROBERT DAVID | WASHINGTON UNIVERSITY, MO | $629,038 | CONC |
| 2019 | Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors1R01CA239257-01A1 | LI, GORDONROSENTHAL, EBEN L. | STANFORD UNIVERSITY, CA | $626,189 | IGIS |
| 2019 | Adoptive T Cell Therapy for Pancreatic Cancer1R01CA237672-01 | YEE, CASSIAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $623,803 | CII |
| 2019 | Novel see and treat strategies for cervical cancer prevention in low-resource settings1R01CA239268-01 | KATZ, DAVID FRANKRAMANUJAM, NIRMALASAPIRO, GUILLERMO R | DUKE UNIVERSITY, NC | $621,096 | MEDI |
| 2019 | Evaluation of Patients with Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI1R01CA230438-01A1 | IAGARU, ANDREI | STANFORD UNIVERSITY, CA | $614,344 | CTIS |
| 2019 | Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed Glioblastoma1R01CA235673-01 | PUDUVALLI, VINAY KSAMPATH, DEEPA | OHIO STATE UNIVERSITY, OH | $603,390 | ZCA1 |
| 2019 | An artificial intelligence-driven distributed stereotactic radiosurgery strategy for multiple brain metastases management1R01CA235723-01 | GU, XUEJUNLU, WEIGUOWARDAK, ZABIHULLAH | UT SOUTHWESTERN MEDICAL CENTER, TX | $599,533 | BCHI |
| 2019 | Chemo-radio immunotherapy for pediatric brain tumors1R01CA229646-01A1 | JOHNSON, THEODORE SMUNN, DAVID H. | AUGUSTA UNIVERSITY, GA | $596,748 | CONC |
| 2019 | Targeting mitochondrial complex I in acute lymphoblastic leukemia1R01CA231364-01A1 | KONOPLEVA, MARINA Y | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $587,548 | DT |
| 2019 | Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy1R01CA229510-01A1 | QUERFELD, CHRISTIANE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $577,137 | CONC |
| 2019 | Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy1R01CA235672-01 | DEHDASHTI, FARROKHLIM, KIAN HLIU, YONGJIAN | WASHINGTON UNIVERSITY, MO | $575,716 | CMIP |
| 2019 | Clinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine Efficacy1R01CA235612-01 | SAMPSON, JOHN H. | DUKE UNIVERSITY, NC | $413,970 | CNBT |
| 2019 | Regulation of Pancreatic Oncogenesis by RIP1 Kinase2R01CA168611-06A1 | COHEN, DEIRDREMILLER, GEORGE | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $381,375 | TME |
| 2019 | Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen1R01CA235622-01 | KONOPLEVA, MARINA YWELCH, JOHN S | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $380,060 | CONC |
| 2019 | Generating a Systemic Immune Response Using Localized Delivery of Chemotherapy in Brain Tumors1R01CA230285-01A1 | LIM, MICHAEL | JOHNS HOPKINS UNIVERSITY, MD | $374,578 | CII |
| 2019 | USING ARGININE METABOLIC THERAPIES FOR SARCOMA1R01CA227115-01A1 | VAN TINE, BRIAN ANDREW | WASHINGTON UNIVERSITY, MO | $364,659 | CONC |
| 2019 | Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity2R01CA168863-06 | LINEHAN, DAVID C | UNIVERSITY OF ROCHESTER, NY | $349,385 | CONC |
| 2019 | Targeting immune stroma interactions in pancreatic cancer1R01CA228406-01A1 | EL-RAYES, BASSELLESINSKI, GREGORY B. | EMORY UNIVERSITY, GA | $343,355 | TME |
| 2019 | Development of a portable and compact robotic system for frameless and maskless stereotactic radiosurgery1R01CA227124-01A1 | WIERSMA, RODNEY | UNIVERSITY OF CHICAGO, IL | $314,632 | BTSS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.